Abstract
Statins (HMG-CoA reductase inhibitors) may decrease inflammation in postacute Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA) and promote vascular remodeling. There are limited data on their safety in young children. Twenty patients with CAAs after KD (median CAA z-score = +25) were treated with 5/10 mg atorvastatin daily for a median of 2.5 years (range 0.5–6.8) starting at a median of 2.3 years (range 0.3–8.9) after acute KD (median age 9.3 years [range 0.7–14.3]). Compliance with treatment was excellent: only one patient reported minor side effects (joint pain, no change in medication). Average total cholesterol before atorvastatin was 3.73 ± 0.84 mmol/L and after atorvastatin was 3.21 ± 0.46 mmol/L (relative decrease −14 %, p = 0.02); low-density lipoprotein cholesterol was 1.99 ± 0.76 mmol/L before and only 1.49 ± 0.27 mmol/L after (relative decrease −20 %, p = 0.04); high-density lipoprotein was 1.39 ± 0.36 mmol/L before and 1.30 ± 0.27 mmol/L after (relative decrease −4 %, p = 0.35); and triglycerides were 0.71 ± 0.28 mmol/L before and 0.71 ± 0.18 mmol/L after (relative decrease −5 %, p = 0.38). Nine of 20 patients (45 %) experienced at least 1 episode of hypocholesterolemia (total cholesterol <3.1 mmol/L), and 2 patients required atorvastatin dose lowering. Transient mild increase of liver enzymes (aspartate aminotransferase/alanine aminotransferase 45–60 U/L) were seen in 7 of 20 (35 %) patients with no patients experiencing more severe increases. Only one patient experienced increased creatine phosphokinase levels (>500 U/L). Serial measurements of age- and sex-specific percentiles of weight (estimated change: 1.4 [2.7] % per year, p = 0.60), height (estimated change: −3.2 [3.2] % per year, p = 0.32), and body mass index (estimated change: 1.0 [2.9] % per year, p = 0.73) showed no association between anthropomorphic growth and atorvastatin treatment. Atorvastatin use in very young children with KD is safe but should be closely monitored.
Similar content being viewed by others
References
Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A et al (2010) Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 55:1121–1126
Blankier S, McCrindle BW, Ito S, Yeung RS (2011) The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol 164:193–201
Carreau V, Girardet JP, Bruckert E (2011) Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Paediatr Drugs 13:267–275
Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L (2011) An 8-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol 32:433–441
Hamaoka A, Hamaoka K, Yahata T, Fujii M, Ozawa S, Toiyama K et al (2010) Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56:245–253
Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J 72:1583–1587
Manlhiot C, Millar K, Golding F, McCrindle BW (2010) Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 31:242–249
Manlhiot C, Niedra E, McCrindle BW (2013) Long-term management of Kawasaki disease: implications for the adult patient. Pediatr Neonatol 54:12–21
McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al (2007) Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115:1948–1967
Mihos CG, Salas MJ, Santana O (2010) The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18:298–304
O’Gorman CS, O’Neill MB, Conwell LS (2010) Considering statins for cholesterol-decrease in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag 7:1–14
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al (2013) ACCF/AHA guideline for the management of ST-increase myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127:529–555
Smaldone C, Brugaletta S, Pazzano V, Luizzo G (2009) Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 7:279–294
Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S et al (2010) Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. doi:10.1002/14651858
Weng KP, Ou SF, Lin CC, Hsieh KS (2011) Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc 74:481–484
Zhou Q, Liao JK (2010) Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74:818–826
Conflict of interest
Brian McCrindle discloses the following potential conflicts of interests regarding this manuscript: consultant for Bristol Myers Squibb, Merck and Eli Lilly, member of data safety and monitoring board for Medpace and receiving research support from Shering Plough and Astra Zeneca.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niedra, E., Chahal, N., Manlhiot, C. et al. Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery Aneurysms. Pediatr Cardiol 35, 89–92 (2014). https://doi.org/10.1007/s00246-013-0746-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-013-0746-9